NCT04384692View on ClinicalTrials.gov

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2029

Conditions
Primary MyelofibrosisSecondary Myelofibrosis
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HSCT

DRUG

Busulfan

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Melphalan

Given IV

DRUG

Methotrexate

Given IV

DRUG

Mycophenolate Mofetil

Given IV or PO

DRUG

Ruxolitinib

Given PO

DRUG

Tacrolimus

Given IV and PO

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Ultrasound Imaging

Undergo ultrasound imaging

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

Fred Hutchinson Cancer Center

OTHER